摘要
目的评价长春西汀（开文通）治疗急性脑梗死的疗效与安全性。方法选择自2010年7月31日至2012年11月27日北京军区总医院等17家医院收治的急性脑梗死患者共610例，经纳入及排除标准遴选后，分成试验N（469例）、对照组（141例）。对照组常规给予口服抗血小板聚集药物。试验组在对照组给药基础上给予长春西汀注射液（开文通）30mg稀释于生理盐水中，缓慢静脉滴注，每天1次，连续14d。采用简易精神状态量表（MMSE）、美国国立卫生研究院卒中量表（NIHSSl、改良的Rankin量表（mRS）及Barthel指数评价疗效。结果治疗后14d，mRS评分试验组（1．85±1．28）优于对照组（1．97±1．23），差异有统计学意义（P〈0．05）。治疗后90d试验组MMSE量表评分（27．42±5．24）、动态NmSS评分（1．37±2．08）和Barthel指数f7．21±17．29）都明显优于对照组[（25．59±7．36）、（2．63±4．98）和（80．60±25．06）]，差异有统计学意义（p〈O．05）。治疗后14d试验组与对照组生化指标比较，差异无统计学意义p0．05）。结论长春西汀（开文通）治疗急性脑梗死患者是安全有效的。
Objective To investigate the efficacy and safety of vinpocetine （Cavinton） in treatment of patients with acute cerebral infarction. Methods Six hundred and ten patients with acute cerebral infarction （within 48 h to 14 d of onset）, admitted to 17 hospitals from July 31, 2010 to November 27, 2012, were recruited and randomly allocated into 2 groups： control group （n=141） and therapy group （n=469）. Patients in the control group were treated with citicoline for 14 d, and those in the therapy group were treated with citicoline combined with 30 mg cavinton via intravenous drip once daily for 14 d. The outcomes were evaluated according to Mini-mental State Examination （MMSE）, National Institute of Heath Stroke Scale （NIHSS）, modified Rankin scale （mRS） and Barthel index before treatment and 7, 14 and 90 d after symptom onset, respectively. Results Significant difference in mRS scores was noted between therapy group （1.85±1.28） and control group （1.97±1.23） 14 d after treatment （/9〈0.05）, There were significant differences in scores of MMSE, NIHSS and Barthel index between therapy group （27.42±5.24, 1.37±2.08 and 7.21 ±17.29） and control group （25.59±7.36, 2.63±4.98 and 80.60±25.06） 90 d after treatment （P〈0.05）. No significant differences in blood biochemical indicators were noted between therapy group and control group （P〉0.05）. Conclusion Treatment with vinpoccetine in patients with acute cerebral infarction is effective.
出处
《中华神经医学杂志》
CAS
CSCD
北大核心
2014年第3期273-276,共4页
Chinese Journal of Neuromedicine
